Siqi Gong1,2, Khamis Tomusange1, Viraj Kulkarni1, Opeyemi S Adeniji1,2, Samir K Lakhashe1, Dinesh Hariraju1, Amanda Strickland1, Elizabeth Plake1, Patrice A Frost3, Sarah J Ratcliffe4, Liping Wang5, Eileen M Lafer5, Ruth M Ruprecht1,2,3. 1. Department of Virology and Immunology, Texas Biomedical Research Institute. 2. Department of Microbiology, Immunology & Molecular Genetics, The University of Texas Health Science Center at San Antonio. 3. Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas. 4. Division of Biostatistics, Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia. 5. Department of Biochemistry and Structural Biology, Center for Biomedical Neuroscience, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Abstract
OBJECTIVE: Worldwide, most new HIV infections occur through mucosal exposure. Immunoglobulin M (IgM) is the first antibody class generated in response to infectious agents; IgM is present in the systemic circulation and in mucosal fluids as secretory IgM. We sought to investigate for the first time the role of IgM in preventing AIDS virus acquisition in vivo. DESIGN: Recombinant polymeric monoclonal IgM was generated from the neutralizing monoclonal IgG1 antibody 33C6-IgG1, tested in vitro, and given by passive intrarectal immunization to rhesus macaques 30 min before intrarectal challenge with simian-human immunodeficiency virus (SHIV) that carries an HIV-1 envelope gene. RESULTS: In vitro, 33C6-IgM captured virions more efficiently and neutralized the challenge SHIV with a 50% inhibitory molar concentration (IC50) that was 1 log lower than that for 33C6-IgG1. The IgM form also exhibited significantly higher affinity and avidity compared with 33C6-IgG1. After intrarectal administration, 33C6-IgM prevented viremia in four out of six rhesus macaques after high-dose intrarectal SHIV challenge. Five out of six rhesus macaques given 33C6-IgG1 were protected at a five times higher molar concentration compared with the IgM form; all untreated controls became highly viremic. Rhesus macaques passively immunized with 33C6-IgM with breakthrough infection had notably early development of autologous neutralizing antibody responses. CONCLUSION: Our primate model data provide the first proof-of-concept that mucosal IgM can prevent mucosal HIV transmission and have implications for HIV prevention and vaccine development.
OBJECTIVE: Worldwide, most new HIV infections occur through mucosal exposure. Immunoglobulin M (IgM) is the first antibody class generated in response to infectious agents; IgM is present in the systemic circulation and in mucosal fluids as secretory IgM. We sought to investigate for the first time the role of IgM in preventing AIDS virus acquisition in vivo. DESIGN: Recombinant polymeric monoclonal IgM was generated from the neutralizing monoclonal IgG1 antibody 33C6-IgG1, tested in vitro, and given by passive intrarectal immunization to rhesus macaques 30 min before intrarectal challenge with simian-human immunodeficiency virus (SHIV) that carries an HIV-1 envelope gene. RESULTS: In vitro, 33C6-IgM captured virions more efficiently and neutralized the challenge SHIV with a 50% inhibitory molar concentration (IC50) that was 1 log lower than that for 33C6-IgG1. The IgM form also exhibited significantly higher affinity and avidity compared with 33C6-IgG1. After intrarectal administration, 33C6-IgM prevented viremia in four out of six rhesus macaques after high-dose intrarectal SHIV challenge. Five out of six rhesus macaques given 33C6-IgG1 were protected at a five times higher molar concentration compared with the IgM form; all untreated controls became highly viremic. Rhesus macaques passively immunized with 33C6-IgM with breakthrough infection had notably early development of autologous neutralizing antibody responses. CONCLUSION: Our primate model data provide the first proof-of-concept that mucosal IgM can prevent mucosal HIV transmission and have implications for HIV prevention and vaccine development.
Authors: Rachael Racine; Maura McLaughlin; Derek D Jones; Susan T Wittmer; Katherine C MacNamara; David L Woodland; Gary M Winslow Journal: J Immunol Date: 2010-12-08 Impact factor: 5.422
Authors: Ronald S Veazey; Robin J Shattock; Melissa Pope; J Christian Kirijan; Jennifer Jones; Qinxue Hu; Tom Ketas; Preston A Marx; Per Johan Klasse; Dennis R Burton; John P Moore Journal: Nat Med Date: 2003-02-10 Impact factor: 53.440
Authors: A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger Journal: J Virol Date: 1996-02 Impact factor: 5.103
Authors: Jennifer D Watkins; Nagadenahalli B Siddappa; Samir K Lakhashe; Michael Humbert; Anton Sholukh; Girish Hemashettar; Yin Ling Wong; John K Yoon; Wendy Wang; Francis J Novembre; Francois Villinger; Chris Ibegbu; Kalpana Patel; Davide Corti; Gloria Agatic; Fabrizia Vanzetta; Siro Bianchi; Jonathan L Heeney; Federica Sallusto; Antonio Lanzavecchia; Ruth M Ruprecht Journal: PLoS One Date: 2011-03-31 Impact factor: 3.240
Authors: Caitlin Bohannon; Ryan Powers; Lakshmipriyadarshini Satyabhama; Ang Cui; Christopher Tipton; Miri Michaeli; Ioanna Skountzou; Robert S Mittler; Steven H Kleinstein; Ramit Mehr; Frances Eun-Yun Lee; Ignacio Sanz; Joshy Jacob Journal: Nat Commun Date: 2016-06-07 Impact factor: 14.919
Authors: Davide Corti; Johannes P M Langedijk; Andreas Hinz; Michael S Seaman; Fabrizia Vanzetta; Blanca M Fernandez-Rodriguez; Chiara Silacci; Debora Pinna; David Jarrossay; Sunita Balla-Jhagjhoorsingh; Betty Willems; Maria J Zekveld; Hanna Dreja; Eithne O'Sullivan; Corinna Pade; Chloe Orkin; Simon A Jeffs; David C Montefiori; David Davis; Winfried Weissenhorn; Aine McKnight; Jonathan L Heeney; Federica Sallusto; Quentin J Sattentau; Robin A Weiss; Antonio Lanzavecchia Journal: PLoS One Date: 2010-01-20 Impact factor: 3.240
Authors: Sanghita Sarkar; Michael S Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C Keefer; Ann J Hessell; Nancy L Haigwood; James J Kobie Journal: Vaccine Date: 2019-03-27 Impact factor: 3.641
Authors: Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope Journal: J Virol Date: 2020-02-14 Impact factor: 5.103
Authors: Siqi Gong; Samir K Lakhashe; Dinesh Hariraju; Hanna Scinto; Antonio Lanzavecchia; Elisabetta Cameroni; Davide Corti; Sarah J Ratcliffe; Kenneth A Rogers; Peng Xiao; Jane Fontenot; François Villinger; Ruth M Ruprecht Journal: Front Immunol Date: 2021-08-03 Impact factor: 7.561
Authors: Zhiqiang Ku; Xuping Xie; Paul R Hinton; Xinli Liu; Xiaohua Ye; Antonio E Muruato; Dean C Ng; Sujit Biswas; Jing Zou; Yang Liu; Deepal Pandya; Vineet D Menachery; Sachi Rahman; Yu-An Cao; Hui Deng; Wei Xiong; Kevin B Carlin; Junquan Liu; Hang Su; Elizabeth J Haanes; Bruce A Keyt; Ningyan Zhang; Stephen F Carroll; Pei-Yong Shi; Zhiqiang An Journal: Nature Date: 2021-06-03 Impact factor: 49.962
Authors: Melanie R Walker; Auda A Eltahla; Michael M Mina; Hui Li; Andrew R Lloyd; Rowena A Bull Journal: Viruses Date: 2020-01-08 Impact factor: 5.048
Authors: Melanie R Walker; Anne S Knudsen; Frederica D Partey; Maria R Bassi; Asger M Frank; Filip C Castberg; Edem W Sarbah; Michael F Ofori; Lars Hviid; Lea Barfod Journal: PLoS One Date: 2020-12-17 Impact factor: 3.240